ArticleEuropean urology open science2025
Clinical and Pathological Features Associated with Chromophobe Renal Cell Carcinoma Recurrence: Analysis from a Nationwide Cohort.
Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Chromophobe renal cell carcinoma (chRCC) is a rare renal malignancy with a generally favourable prognosis. However, a subset of patients experiences recurrence, which remains poorly characterised. This study aims to identify the clinicopathological factors associated with recurrence in chRCC, describe the timing and anatomical patterns of recurrence, and develop a predictive model to guide surveillance strategies. Methods: We conducted a multicentre retrospective cohort study using data from the French UroCCR database, including patients treated surgically for nonmetastatic chRCC between 2010 and 2024. Clinicopathological features, recurrence-free survival (RFS), cancer-specific survival, and overall survival were analysed. Kaplan-Meier survival curves and multivariable Cox proportional-hazard models were used to assess prognostic factors. Key findings and limitations: Among the included 683 patients, 43 (6.3%) developed recurrence, with median RFS of 142 mo (95% confidence interval [CI] 121-not reached). Local recurrence was observed in 30 patients, while 18 developed distant metastases, predominantly in the retroperitoneal lymph nodes and lungs. Male sex (hazard ratio [HR] 3.1, 95% CI 1.27-7.54, Conclusions and clinical implications: This study provides novel insights into the recurrence patterns of chRCC, highlighting the key prognostic factors. The proposed predictive model was designed to aid clinicians in identifying high-risk patients, optimising follow-up intensity, and guiding therapeutic decisions. Patient summary: We studied a rare kidney cancer type, called chromophobe renal cell carcinoma (chRCC), to understand why some patients experience recurrence. We found that being male, having advanced disease, or some aggressive pathological characteristics increased the risk of cancer coming back. Our results suggest that doctors should monitor certain patients more closely after surgery. This research may help improve long-term follow-up and treatment plans for patients with chRCC. While certain factors are associated with a higher risk of recurrence, it is important to note that chromophobe renal cell carcinoma generally has a favourable prognosis, and the absolute risk of recurrence remains low for most patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.